Xi Cheng

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 9

Top Topics

Transcription Factor

Acute Lymphoblastic Leukemia

Cell Proliferation

Top Venues

Cell death & disease

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Chao Li, Zichao Guo, Sisi Pu, Chaohui Zhou, Xi Cheng, Ren Zhao, Nengqin Jia
Molybdenum Disulfide-Integrated Iron Organic Framework Hybrid Nanozyme-Based Aptasensor for Colorimetric Detection of Exosomes. Biosensors 13 (8) (2023)
Yu Heng, Zheyu Yang, Pengyu Cao, Xi Cheng, Lei Tao
Lateral Involvement in Different Sized Papillary Thyroid Carcinomas Patients with Central Lymph Node Metastasis: A Multi-Center Analysis. Journal of clinical medicine 11 (17) (2022)
Juyong Liang, Zhijian Jin, Jie Kuang, Haoran Feng, Qiwu Zhao, Zheyu Yang, Ling Zhan, Baiyong Shen, Jiqi Yan, Wei Cai, Xi Cheng, Weihua Qiu
The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. British journal of cancer 125 (3) (2021)
Yi Peng, Haoran Feng, Changgang Wang, Zijia Song, Yaqi Zhang, Kun Liu, Xi Cheng, Ren Zhao
The role of E26 transformation-specific variant transcription factor 5 in colorectal cancer cell proliferation and cell cycle progression. Cell death & disease 12 (5) (2021)
Haoran Feng, Zhijian Jin, Juyong Liang, Qiwu Zhao, Ling Zhan, Zheyu Yang, Jiqi Yan, Jie Kuang, Xi Cheng, Weihua Qiu
FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway. Oncogene 40 (42) (2021)
Jinsoo Song, Sujeong Park, Jinjoo Oh, Deokha Kim, Ji Hyun Ryu, Won Cheol Park, In-Jeoung Baek, Xi Cheng, Xin Lu, Eun-Jung Jin
NUDT7 Loss Promotes KrasG12D CRC Development. Cancers 12 (3) (2020)
Zhijian Jin, Haoran Feng, Juyong Liang, Xiaoqian Jing, Qiwu Zhao, Ling Zhan, Baiyong Shen, Xi Cheng, Liping Su, Weihua Qiu
FGFR3△7-9 promotes tumor progression via the phosphorylation and destabilization of ten-eleven translocation-2 in human hepatocellular carcinoma. Cell death & disease 11 (10) (2020)
Haoran Feng, Kun Liu, Xiaonan Shen, Juyong Liang, Changgang Wang, Weihua Qiu, Xi Cheng, Ren Zhao
Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer. Cell death & disease 11 (10) (2020)
Haoran Feng, Kun Liu, Xiaonan Shen, Juyong Liang, Changgang Wang, Weihua Qiu, Xi Cheng, Ren Zhao
Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer. Cell death & disease 11 (11) (2020)